Astrocytes limit inflammation after CNS injury, at least partially by physically containing it within an astrocytic scar at the injury border. We report here that astrocytic transforming growth factor-beta (TGFb) signaling is a second, distinct mechanism that astrocytes utilize to limit neuroinflammation. TGFbs are anti-inflammatory and neuroprotective cytokines that are upregulated subacutely after stroke, during a clinically accessible time window. We have previously demonstrated that TGFbs signal to astrocytes, neurons and microglia in the stroke border days after stroke. To investigate whether TGFb affects astrocyte immunoregulatory functions, we engineered "Ast-Tbr2DN" mice where TGFb signaling is inhibited specifically in astrocytes. Despite having a similar infarct size to wildtype controls, Ast-Tbr2DN mice exhibited significantly more neuroinflammation during the subacute period after distal middle cerebral occlusion (dMCAO) stroke. The peri-infarct cortex of Ast-Tbr2DN mice contained over 60% more activated CD11b 1 monocytic cells and twice as much immunostaining for the activated microglia and macrophage marker CD68 than controls. Astrocytic scarring was not altered in Ast-Tbr2DN mice. However, AstTbr2DN mice were unable to upregulate TGF-b1 and its activator thrombospondin-1 2 days after dMCAO. As a result, the normal upregulation of peri-infarct TGFb signaling was blunted in Ast-Tbr2DN mice. In this setting of lower TGFb signaling and excessive neuroinflammation, we observed worse motor outcomes and late infarct expansion after photothrombotic motor cortex stroke. Taken together, these data demonstrate that TGFb signaling is a molecular mechanism by which astrocytes limit neuroinflammation, activate TGFb in the peri-infarct cortex and preserve brain function during the subacute period after stroke.
Introduction
A strocytes are uniquely positioned to regulate inflammatory responses after CNS injury. They become activated during the subacute period after injury that is characterized by neuroinflammation (Barreto et al., 2011; Chen and Swanson, 2003 ) and respond to injury in a highly localized manner. Previous research in our laboratory demonstrated that after stroke astrocytes in the peri-infarct cortex respond to the major regulatory cytokine transforming growth factor-beta (TGFb), as measured by nuclear localization of its downstream mediator phosphorylated Smad2 (pSmad2) in glial fibrillary acidic protein (GFAP)-expressing astrocytes (Doyle et al., 2010; Massagu e and Wotton, 2000) . However, the functions of astrocytic TGFb signaling during the subacute period after stroke remain to be discovered.
Astrocytes react to injury by increasing GFAP expression. GFAP 1 astrocytes eventually form a physical barrier, also known as the astrocytic scar, which limits immune cell infiltration and protects adjacent uninjured tissue (Schachtrup et al., 2010; Sofroniew and Vinters, 2010) . This process of astrocytic scar formation requires astrocytic STAT3 and GFAP (Li et al., 2008; Wanner et al., 2013) . In addition to forming a scar, astrocytes respond to CNS injury by producing proinflammatory cytokines and chemokines. For example, astrocytes produce the chemokines CCL2, CXCL1 and CXCL2 after ischemia or spinal cord injury (Pineau et al., 2010; Zamanian et al., 2012) , and CCL2 and CCL5 after traumatic brain injury (Babcock et al., 2003; Glabinski et al., 1996) . These pro-inflammatory chemokines may be beneficial by attracting immune cells, which have been shown to reduce tissue damage by clearing dead cells (Dheen et al., 2007; Iadecola and Anrather, 2011) . In contrast, excessive inflammation can be harmful by inducing free-radical damage to neurons (Brown, 2010) and increasing cerebral edema, which can cause brain herniation and further tissue damage (Heiss, 2012) . Therefore, it is essential to limit neuroinflammation during the subacute period after injury in order to reduce neuronal damage.
We hypothesized that the activation of astrocytic TGFb signaling that we observed in the subacute period after stroke might represent an active anti-inflammatory function of astrocytes. The TGFb isoform TGF-b1 is upregulated by the majority of brain injuries (Finch et al., 1993) and signals to all cell types in the injured brain (Buckwalter and WyssCoray, 2004; Pratt and McPherson, 1997) . It is specifically increased during the subacute period that coincides with neuroinflammation after stroke (Yamashita et al., 1999) . TGFbs have anti-inflammatory functions in the immune system (Crowe et al., 2000; Fadok et al., 1998) and are acutely neuroprotective at the time of stroke (Pang et al., 2001; Ruocco et al., 1999) . However, TGFb functions in astrocytes during the subacute period after stroke are not known.
To investigate how endogenous TGFb signaling regulates astrocyte function after stroke in vivo, we engineered a transgenic mouse model to inhibit TGFb signaling in GFAP 1 astrocytes during the subacute period after stroke by expressing a mutant receptor that is unable to initiate downstream signaling when bound by either TGFb isoform (Frugier et al., 2005; Shi and Massague, 2003) . Temporal specificity was achieved using a GFAP promoter that is upregulated in the peri-infarct cortex during this time. We demonstrate that inhibiting astrocytic TGFb signaling resulted in excessive immune cell infiltration and activation 2-3 days after stroke. This increase in neuroinflammation was not associated with changes in infarct size, or in astrocytic GFAP upregulation and scar formation. However, inhibiting TGFb signaling abolished the normal upregulation of TGF-b1 and its activator thrombospondin-1, and blunted TGFb pathway activation in the peri-infarct cortex. Finally, inhibiting astrocytic TGFb signaling was also associated with worse motor outcomes. We conclude that TGFb signaling is critical for astrocytic control of neuroinflammation and preserving function in the peri-infarct cortex during the subacute period after stroke.
Materials and Methods

Mice
All use of animals was conducted according to protocols approved by the Stanford Institutional Animal Care and Use Committee and the NIH Guide for Care and Use of Animals. Ast-Tbr2DN transgenic mice were a cross between the lines B6.FVB-Tg(tetO-EGFP,-Tgfbr2)8Mcle/J (JAX #005738) and B6.Cg-Tg(GFAP-tTA)110Pop/J (JAX #005964), both obtained from Jackson Labs. The first line (Frugier et al., 2005; Lin and Yang, 2013; Rani et al., 2011) carries a bitetO promoter that drives the expression of two genes: a dominant negative mutant Type II TGFb receptor, which has a truncated intracellular domain and prevents all TGFb signaling (Shi and Massague, 2003) , and enhanced green fluorescent protein (eGFP). Thus, eGFP expressing cells are also expected to express high levels of the mutant receptor. The second transgenic line expresses GFAP-tTA, which directs bi-tetO promoter-mediated expression to GFAP 1 astrocytes (Florian et al., 2011; Halassa et al., 2009; Pascual et al., 2005) . Similar to the native GFAP promoter, the GFAP promoter in GFAP-tTA mice strongly increases transgene expression after injury (Brenner et al., 1994) . All experiments were done using 2-month-old females. Singly transgenic B6.FVB-Tg(tetO-EGFP,-Tgfbr2)8Mcle/J mice were used as wildtype littermate controls.
Surgery
Distal middle cerebral artery occlusion (dMCAO) strokes were induced as previously described (Doyle et al., 2010) . For photothrombotic stroke, the skull was cleaned of connective tissue and lightly shaved using a sterile razor blade. The Dolan-Jenner MH-100 Metal Halide Fiber Optic Illuminator (Edmundoptics, #56371) light source with a 5-mm diameter optic cable (Edmundoptics, #39365) was placed on top of the skull and 403 microscope objective was used to focus the light. The light was turned on twice for 15 min, beginning 5 min after a 40 mg kg 21 Rose Bengal (Sigma, #330000-5G) injection (10 mg mL 21 in sterile saline, administered intraperitoneally), to form two overlapping circular lesions in the right motor cortex. Body temperature was maintained at 37 C, and immediately following surgery mice received 10 mg kg 21 of Cefazolin (VWR, #89149-888) and 0.1 mg kg 21 of Buprenorphine (Henry Schein, #6030894) for infection prophylaxis and pain management.
Flow Cytometry
We homogenized the stroked hemisphere and collected a monocyteenriched population of cells using a Percoll gradient (Arac et al., 2011) . The cells were stained with the following markers and antibodies: AquaAmine Live/Dead stain (Invitrogen, #L34957) CD11b-PE (eBioscience, #12-0112-82) and CD45-APC (eBioscience, #17-0451-82), counted on the FACSAria III cell sorter (BD Biosciences) and analyzed using FlowJo software (TreeStar).
Perfusion and Brain Processing for Immunohistochemistry
Mice were sedated with 3.8% chloral hydrate and terminally perfused with 0.9% NaCl containing 10 U mL 21 heparin. Brains were fixed in 4% paraformaldehyde in phosphate buffer for 24 h, rinsed with PBS, and then sunk in 30% sucrose in PBS. Coronal brain sections 40-lm thick were cut using a freezing sliding microtome (Microm HM430) into 24 sequential tubes, so that each tube contained every 24th section spaced 960-lm apart, and were stored in cryoprotective medium at 220 C.
Immunohistochemistry
We analyzed images with MetaMorph and ImageJ software. We evaluated GFAP colocalization with eGFP and with pSmad2 in four coronal sections per mouse, evenly spaced 480-lm apart. To avoid bias, co-localization of pSmad2 with GFAP was scored first, and eGFP expression was examined afterwards. We quantified CD68 immunostaining in the peri-infarct cortex in five sections per mouse at 2.53 magnification, evenly spaced 960-lm apart. We quantified GFAP immunostaining in the peri-infarct cortex in two sections per mouse at 2.53 magnification, 960-lm apart. We counted MHCII 1 cells in three sections per mouse 960-lm apart.
Infarct Size Evaluation
Infarct size was quantified using an immunostain with an anti-NeuN antibody that marks neuronal nuclei, counterstained with cresyl violet, which marks all cell nuclei. The infarct was traced on six sections per mouse, 480-lm apart, and expressed as % of the ipsilateral hemisphere after dMCAO (Woo et al., 2012) or as volume after photothrombotic stroke (Clarkson et al. 2011) .
Antibodies
We used the following primary antibodies for immunohistochemistry: anti-phosphorylated Smad2 (rabbit, 1:1000, Millipore, #AB3849), anti-GFAP (rabbit, 1:1000, DAKO, #Z0334), biotinylated anti-GFAP (mouse, 1:200, Abcam, #ab79203), anti-eGFP (chicken, 1:200, Millipore, #AB16901), biotinylated anti-NeuN (mouse, 1:200, Millipore, #MAB377B), anti-CD68 (rat, 1:1000, Serotec, #MCA1957S), anti-MHCII (rat, 1:500, BD Pharmingen, #553621), anti-NG2 (rabbit, 1:500, Millipore, #AB5320), and antiphosphoAkt (rabbit, 1:1000, Abcam, #ab81283). We used the following secondary antibodies for immunohistochemistry: AlexaFluor-488 donkey anti-chicken (Jackson Immunoresearch, #703-096-155), AlexaFluor-555 streptavidin (Invitrogen/ Molecular Probes, #S-32355), AlexaFluor-555 donkey anti-rabbit (Invitrogen, #A31572), AlexaFluor-555 donkey anti-rat (Jackson Immunoresearch, #712-165-153), AlexaFluor-647 donkey anti-rabbit (Invitrogen, #A-31573), AlexaFluor-647 streptavidin (Invitrogen/ Molecular Probes, #S-21374), and biotinylated rabbit anti-rat (Vector Laboratories, #BA-4001).
We used the following antibodies for Western blots: phosphorylated Smad2 (rabbit, 1:200, Millipore, #AB3849), Smad2 (rabbit, 1:200, Cell Signaling, #3122), phosphorylated Akt (mouse, 1:200, Cell Signaling, #4051), Akt (rabbit, 1:200, Cell Signaling, #9272), actin (rabbit, 1:20,000, Sigma, #A5060), goat anti-rabbit HRP (1:20,000, Santa Cruz, #sc-2004) and goat anti-mouse HRP (1:20,000, DAKO, #P0447). Actin was used as a loading control. All secondary antibodies were used at 1:200 dilution.
Sample Preparation for Protein and mRNA Measurements
After perfusion, we dissected tissue samples from the peri-infarct cortex and the contralateral cortex directly opposite the stroke core, as well as from cortex and striatum in sham mice. The peri-infarct cortex was defined as the cortical area within 2.5-mm radius from the stroke core at the time of tissue extraction.
For protein assays, tissue was flash frozen and kept at 280 C until homogenization in cell lysis buffer with Complete Mini protease inhibitor (Roche, #11836153001) and 0.1% Na 3 VO 4 . Samples were sonicated for 10 s, centrifuged at 14,000 rpm for 10 min, and the protein concentration in the supernatant was equalized using a BCA Pierce protein assay kit (ThermoScientific, #23227). Four to six animals per group were used for all protein assays. For Western blots, tissue lysates were mixed with 20% dithiothreitol in 43 NuPage LDS loading buffer (Invitrogen, #NP0007). Samples were loaded onto 4-12% NuPage BisTris gels (Invitrogen, #NP0335) and subsequently transferred onto polyvinylidene fluoride membranes (Amersham, #RPN303F).
Multiplex Luminex Assay and ELISA
Multiplex luminex assay was performed by the Human Immune Monitoring Center at Stanford University (himc.stanford.edu). Each sample was measured in duplicate. Plates were read using a Luminex 200 instrument with a lower bound of 100 beads per sample per cytokine. Results were analyzed using Cluster 3.0 and visualized using JavaTreeView software. TGF-b1 protein concentration was measured using a Mouse/Rat/Porcine/Canine TGF-b1 Quantikine ELISA kit (R&D Systems, #MB100B). To activate latent TGF-b1, protein samples were activated by 1M HCl and quenched by 1M NaOH, following the manufacturer's instructions.
Quantitative RT-PCR
We isolated mRNA and performed qPCR as previously described (Shi et al., 2010) . We quantified the expression of the following genes: thrombospondin-1 (Thbs1-001, RefSeq mRNA: NM_011580.3, forward primer: 5 0 -GCAAAGACTGTGTTGGCGATGTGA-3 0 , reverse We used GAPDH as a control (Gapdh-001, RefSeq mRNA: NM_008084.2, forward primer:
Behavioral Scores
For the beam balance test (Manaenko et al., 2011) we used the following scoring system: 5-mice move across the beam to their home cage in 6 s, 4-mice move to their home cage in 11 s or within 6 s but do not get into the cage, 3-mice move more than half the distance to their home cage within 11 s and stay on the beam for at least 6 s, 2-mice do not move more than half the distance to their home cage within 11 s and stay on the beam for at least 6 s, 1-mice do not move, but stay on the beam for 11 s, 0-mice fall off the beam within 11 s. The Modified Garcia Score is a well-established sensorimotor assessment system consisting of seven individual tests, of which we used the 5 that measure motor function (Doyle et al., 2012; Garcia et al., 1995) . We scored each test from 0 to 3 (maximal score 5 15): (1) climbing, (2) forelimb walking, (3) forelimb strength, (4) lateral turning, and (5) limb symmetry as described (Doyle et al., 2012) .
Statistical Analysis
All experimental data were acquired in a blinded and unbiased fashion. Statistical analyses were performed using Prism 6 software (GraphPad). Means between two groups were compared using twotailed, unpaired Student's t test for parametric data, and MannWhitney test for nonparametric data. Means between more than two groups were compared using one-way ANOVA with Bonferroni correction for multiple comparisons. Comparisons of means from two genotypes at multiple timepoints were performed using two-way ANOVA when mouse cohorts were different at each timepoint, and repeated measures ANOVA when the same mice were used throughout the course of the experiment. For cluster analysis, cytokine detection in 80% of samples was used as a threshold, and the difference between clusters was computed based on Pearson's correlation.
Results
Construction of an "Ast-Tbr2DN" Mouse Model to Inhibit Astrocytic TGFb Signaling To investigate astrocytic TGFb signaling after stroke, we selected the model of distal middle cerebral artery occlusion (dMCAO) (Colak et al., 2011) . The advantages of dMCAO are that it is directly caused by arterial occlusion and produces a highly consistent stroke with a clearly defined border. We previously reported that TGFb signaling increases in GFAP 1 astrocytes in the periinfarct cortex during the first week after dMCAO, as represented by nuclear localization of pSmad2 (Doyle et al., 2010) (Fig. 1A) .
To study the function of endogenous astrocytic TGFb signaling after stroke, we engineered a dominant negative (Ast-Tbr2DN) transgenic mouse model that inhibits TGFb signaling specifically in GFAP 1 astrocytes (Fig. 1B) . Adult Ast-Tbr2DN mice were indistinguishable from wildtypes prior to stroke based on gross anatomy, expression of GFAP, immune cell markers and cytokines, and motor function (data not shown). We verified that stroke upregulates the transgene specifically in GFAP 1 astrocytes by coimmunostaining for GFAP and the transgene marker eGFP. We observed that eGFP expression was present at baseline in 10% of astrocytes. As expected, transgene expression significantly increased after dMCAO in the peri-infarct cortex (Fig. 1C ).
FIGURE 1: TGFb signaling is specifically inhibited in astrocytes in Ast-Tbr2DN mice. A. Representative images of the TGFb pathway activation marker pSmad2 co-localized with a GFAP 1 cell nucleus in the peri-infarct cortex of a wildtype mouse 24 h after dMCAO. Note that astrocytes are not the only cell types responding to TGFb. Arrow, a GFAP 1 cell expressing pSmad2 after dMCAO. Scale bar, 20 lm. B. Diagram of the AstTbr2DN mouse model. The tetracycline transactivator protein (tTA) is driven by a GFAP promoter. tTA then binds the bidirectional bi-tetO promoter to drive two genes, eGFP and the dominant negative mutant type II TGFb receptor, Tbr2DN. C. Representative images of eGFP expression in Ast-Tbr2DN mice in uninjured cortex (sham) and in the peri-infarct cortex 2 days after dMCAO (D2). Scale bar, 200 lm. D. Representative images showing specific eGFP expression in GFAP 1 cells in Ast-Tbr2DN mice. Scale bar, 50 lm. E, F. eGFP 1 astrocytes in Ast-Tbr2DN mice are less likely to demonstrate nuclear expression of pSmad2 than controls 24 h after dMCAO. Representative images (E) and quantification (F). Arrow head, a typical GFAP 1 /eGFP 1 cell that does not express nuclear pSmad2. Scale bar, 20 lm. N 5 4 mice per group, 100 GFAP 1 cells per mouse. Bars, mean 6 SEM. *P < 0.05, **P < 0.01, one-way ANOVA, Bonferroni correction to compare with sham or wildtype.
eGFP expression was completely specific to astrocytes at all timepoints and did not co-localize with any other cell types ( Fig. 1D and data not shown) .
To verify that the mutant TGFb receptor was functional in reducing TGFb signaling in eGFP 1 astrocytes in AstTbr2DN mice, we immunostained for the downstream TGFb signaling marker nuclear pSmad2 and quantified its colocalization with GFAP and with eGFP in the peri-infarct cortex. To avoid bias, we scored the colocalization of pSmad2 and GFAP prior to examining eGFP. Significantly fewer GFAP 1 /eGFP 1 astrocytes in Ast-Tbr2DN mice co-localized with nuclear pSmad2 when compared with astrocytes in wildtype mice (Fig. 1E,F) . By contrast, GFAP 1 /eGFP 2 astrocytes in Ast-Tbr2DN mice showed the same proportion of nuclear pSmad2 as astrocytes in wildtype mice (Fig. 1F) . Thus, in Ast-Tbr2DN mice the mutant type II TGFb receptor blocks TGFb signaling in GFAP 1 /eGFP 1 astrocytes.
Inhibiting Astrocytic TGFb Signaling Increases the Magnitude and Spread of Inflammation in the Peri-Infarct Cortex
We next investigated whether normal astrocytic TGFb signaling is required to limit neuroinflammation after stroke. Two FIGURE 2: Inhibiting astrocytic TGFb signaling increases inflammation in the peri-infarct cortex during the subacute period after dMCAO. A, B. Representative flow cytometry plots (A) and quantification (B) of CD11b 1 CD45 medium and CD11b 1 CD45 high monocytes in the peri-infarct cortex of Ast-Tbr2DN mice and wildtype controls. C. Representative images of CD68 immunostaining along the rostralcaudal axis across the peri-infarct cortex 3 days after dMCAO. The coronal section showing the largest stroke was arbitrarily designated as 0 lm, and CD68 1 cell activation was more prominent in Ast-Tbr2DN mice both rostral (21,920 lm) and caudal to that location (11,920 lm) Scale bar, 200 lm. D. Quantification of CD68 immunostaining 3 days after dMCAO in the peri-infarct cortex, extending 1,920 lm rostral and caudal from the section with maximal stroke size, demonstrates much more extensive spread of CD68 activation in Ast-Tbr2DN mice. E, F. Representative images (E) and quantification (F) of MHC II immunostaining in the peri-infarct cortex 3 days after dMCAO. Scale bar, 100lm. G. Quantification of iNOS mRNA in Ast-Tbr2DN mice and wildtype controls. N 5 6-12 mice per group. Bars, mean 6 SEM. *P < 0.05, Student's t test.
days after stroke the immune response consists predominantly of activated monocytic cells, both CNS microglia and peripheral macrophages (Denker et al., 2007; Iadecola and Anrather, 2011; Stevens et al., 2002) . We used FACS to count activated microglia and macrophages in the stroked hemisphere of AstTbr2DN mice and wildtype controls ( Fig. 2A,B) . CD11b 1 cells with medium CD45 expression were classified as activated CNS microglia, and CD11b 1 cells with high CD45 expression as peripheral macrophages (Mizutani et al., 2012) . The stroked hemisphere of Ast-Tbr2DN mice contained significantly (67%) more cells in combined microglial and macrophage populations, with a particularly pronounced 110% increase in macrophages (Fig. 2B) .
To assess whether inhibiting astrocytic TGFb signaling affected the localization as well as the magnitude of the immune cell infiltration, we immunostained for CD68, which is a marker for activated microglia and macrophages. CD68 1 cells with activated amoeboid morphology were present in the peri-infarct cortex in both genotypes. We quantified the percentage of cortical area that was covered by CD68 immunostaining in a series of sections spanning the entire stroke region. In keeping with the flow cytometry results, the area covered by CD68 1 cells was 1.9-fold larger in Ast-Tbr2DN peri-infarct cortex as in wildtype controls (Fig. 2C,D) .
To verify this increased spread of activated monocytic lineage cells, and to examine their activation state, we examined immunostaining for major histocompatibility complex class II (MHC II). MHC II regulates antigen presentation and is used as a marker for proinflammatory microglia and macrophages (Mantovani et al., 2004) . As with the activated microglia and macrophage cell counts, and the CD68 immunostaining, we observed almost twice as many MHC II 1 cells in the peri-infarct cortex of Ast-Tbr2DN mice as in wildtype controls (Fig. 2E,F) . Furthermore, MHC II 1 cells, like CD68 1 cells, appeared to be disseminated further from the infarct in Ast-Tbr2DN mice. Activated microglia and macrophages also express inducible nitric oxide synthase (iNOS) (Kigerl et al., 2009; Mantovani et al., 2004 ) which leads to free radical formation and increases neuronal damage (Brown, 2010) . To assess whether inhibiting astrocytic TGFb signaling increases iNOS expression after stroke, we used qPCR to measure iNOS mRNA levels in the peri-infarct cortex of Ast-Tbr2DN and wildtype mice (Fig. 2G) . We observed twofold more iNOS mRNA in Ast-Tbr2DN than wildtype mice after stroke, which approximately correlates with the increased number of activated microglia and peripheral macrophages (Fig. 2B,D,F) . These findings indicate that inhibiting astrocytic TGFb signaling increases the magnitude and the extent of inflammation in the peri-infarct cortex as well as its potential neurotoxicity via iNOS production.
Inhibiting Astrocytic TGFb Signaling Does Not Affect Initial Stroke Size or Astrocytic Activation in the Peri-Infarct Cortex One possible reason for a larger immune response in AstTbr2DN mice could be a larger stroke. However, at this timepoint, 2 days after stroke, when we observed increased FIGURE 3: Inhibiting astrocytic TGFb signaling does not affect stroke size or early astrocytic scar formation after dMCAO. A. Quantification of infarct size in Ast-Tbr2DN mice and wildtype controls. B, C. Representative images (B) and quantification (C) of reactive astrocyte marker GFAP expression in the peri-infarct cortex of Ast-Tbr2DN mice and wildtype controls 3 days after dMCAO. Scale bar, 500 lm. D, E. Quantification of glial scar components fibronectin-1 (D) and tenascin-C (E) mRNA levels 2 days after dMCAO.
inflammation, stroke sizes were not different between genotypes (Fig. 3A) .
A second possibility that could explain more immune cells in the brain after stroke might be an inadequate physical astrocytic barrier (Voskuhl et al., 2009; Wanner et al., 2013) . However, we did not observe any morphological differences in GFAP 1 astrocytes between genotypes, including in the peri-infarct cortex. Furthermore, there were no genotypedependent differences in % area covered by GFAP immunostaining in the peri-infarct cortex 3 days after stroke (Fig. 3B,C) . Finally, we did not observe any differences between genotypes in GFAP immunostaining even after the immune response largely subsided, 7 days after stroke (wildtype: 12.59% 6 1.44%, Ast-Tbr2DN: 15.13% 6 2.23%, P 5 0.37).
To perform a more thorough evaluation of early astrocyte activation and barrier formation, we also measured two extracellular matrix proteins that are upregulated in astrocytes during the subacute period after CNS injury (Schachtrup et al., 2010; Smith and Hale, 1997; Zamanian et al., 2012) : FIGURE 4: Astrocytic TGFb signaling is required to upregulate functional TGFb in the peri-infarct cortex during the subacute period after dMCAO. A. Cluster analysis of cytokine and chemokine expression in the peri-infarct and contralateral cortex of Ast-Tbr2DN mice and wildtype controls 2 days after dMCAO using a luminex assay. Heat map represents log 2 levels of normalized protein expression. White squares, protein not detectable. White rectangle indicates TGF-b1, which was the only cytokine that was significantly different between Ast-Tbr2DN mice and wildtype controls. B. Quantification of TGFb levels in the peri-infarct cortex of Ast-Tbr2DN mice and wildtype controls 2 days after dMCAO using a luminex assay. C. Quantification of TGF-b1 levels in the peri-infarct cortex at baseline and 2 days after dMCAO using ELISA with acid activation step. D. Quantification of mRNA levels of the TGFb activator thrombospondin-1 (Thbs1) in AstTbr2DN mice and wildtype controls at baseline and 2 days after dMCAO. N 5 5-6 mice per group. Bars, mean 6 SEM. *P < 0.05, **P < 0.01, ***P < 0.001, Student's t test and two-way ANOVA (interaction between genotype and time).
fibronectin-1 and tenascin C. As with GFAP, there was no difference in expression of either gene in Ast-Tbr2DN mice compared with wildtype controls (Fig. 3D,E) . Thus, our results suggest astrocytic TGFb signaling during the subacute period after stroke did not alter neuroinflammation by altering the astrocytic scar.
Astrocytic TGFb Signaling is Required to Upregulate the Expression of TGF-b1 and its Activator Thrombospondin-1 in the Peri-Infarct Cortex during the Subacute Period after Stroke Because astrocytes respond to CNS injury by producing cytokines and chemokines, we next investigated whether inhibiting astrocytic TGFb signaling could increase inflammation by altering the cytokine milieu in the peri-infarct cortex. We measured a panel of 26 distinct pro-and anti-inflammatory cytokines and chemokines in the peri-infarct and contralateral cortex 2 days after stroke using a multiplex luminex assay. Three of these cytokines (IL-3, IL-10, and GCSF) were undetectable in the peri-infarct cortex.
Unbiased cluster analysis of the remaining 23 proteins revealed distinct patterns of expression based on genotype (Fig. 4A) . However, TGF-b1 itself was the only cytokine that, on an individual basis, showed significant genotypedependent differences, and thus it was the main factor that influenced sample clustering. There was a threefold reduction in TGF-b1 in the Ast-Tbr2DN peri-infarct cortex compared with wildtype (Fig. 4B) , suggesting that inhibiting astrocytic TGFb signaling disrupts a feed-forward mechanism by which TGFb signaling in astrocytes normally propagates its own upregulation after stroke. We confirmed by ELISA that AstTbr2DN mice have normal levels of TGF-b1 before stroke, but then fail to upregulate it normally in the peri-infarct cortex (Fig. 4C) .
Of the 3 TGFb isoforms, TGF-b1 is the one most upregulated by injury, including stroke in both animal models and human patients (Dhandapani and Brann, 2003; Finch et al., 1993; Krupinski et al., 1996) , though TGF-b2 can also be increased by stroke (Vivien and Ali, 2006) . To investigate whether TGFb mRNA is upregulated by dMCAO, and whether astrocytic TGFb signaling reduces its expression at an mRNA level as well as protein level, we quantified the expression of TGF-b1, 2 and 3 mRNA by qPCR. We found that both TGF-b1 and TGF-b2, but not TGF-b3 in wildtype mice are significantly increased by 2 days after dMCAO (TGF-b1: 3.55 6 0.70-fold, *P 5 0.011; TGF-b2: 2.24 6 0.26-fold, **P 5 0.0028; TGF-b3: 0.92 6 0.15-fold, P 5 0.82, Student's t test). However, we did not observe any differences between Ast-Tbr2DN mice and wildtype controls in either TGF-b1 or TGF-b2 mRNA expression (data not shown). In addition, TGF-b1 was the isoform that was most highly expressed after stroke, as its mRNA was expressed at 95.01 6 1.22-fold higher level than TGF-b2 mRNA. Thus, astrocytic TGFb signaling is required to induce TGF-b1 production primarily at the protein rather than the mRNA level.
After secretion TGF-b1 is stored in an inactive form in a latent complex that is bound to the extracellular matrix. This latent store of TGF-b1 requires activation in order to initiate TGFb signaling (Annes et al., 2003) . One major TGFb activator is thrombospondin-1, which initiates protease-mediated cleavage of TGFb from the latent complex and serves as the main TGFb activator in vivo (Crawford et al., 1998) . In addition, TGF-b1 is known to stimulate the production of thrombospondin-1 by astrocytes (Cambier et al., 2005; Yonezawa et al., 2010) . Therefore, we investigated thrombospondin-1 as a potential astrocytic TGFbsignaling dependent activator of TGF-b1 in the peri-infarct cortex.
We found that Ast-Tbr2DN mice fail to upregulate thrombospondin-1 mRNA 2 days after stroke, while wildtype mice upregulate it fivefold (Fig. 4D) . This finding suggests that after stroke astrocytic TGFb signaling participates in a positive feedback loop where it is required to upregulate both TGF-b1 and also its activator thrombospondin-1. There is one other TGFb activator that is produced by astrocytes, integrin b8 (Cambier et al., 2005; Mu et al., 2002) . However, we observed no significant difference in integrin b8 mRNA between Ast-Tbr2DN mice and wildtype controls 2 days after stroke (wildtype: 1.04 6 0.155, Ast-Tbr2DN: 1.02 6 0.148).
Ast-Tbr2DN Mice Exhibit a Global Reduction in TGFb Signaling after Stroke
TGFb signaling is upregulated subacutely in peri-infarct cortex in wildtype mice (Doyle et al., 2010) . To evaluate whether the relative deficiency of TGF-b1 and thrombospondin-1 in Ast-Tbr2DN mice caused an overall reduction in downstream TGFb signaling in the peri-infarct cortex, we examined Smad2 phosphorylation by Western blot. As with TGF-b1 protein levels, there was no difference before stroke (Fig. 5A,B) . However, 2 days after stroke, Smad2 phosphorylation was significantly reduced in the AstTbr2DN peri-infarct cortex (Fig. 5C,D) , consistent with a decrease in TGF-b1 and its activator thrombospondin-1. By 7 days after stroke, thrombospondin-1 mRNA in AstTbr2DN mice reached wildtype levels (normalized WT: 1.00 6 0.23, Ast-Tbr2DN: 1.36 6 0.27, P 5 0.35). At this later timepoint, Smad2 phosphorylation also returned to normal (normalized WT: 1.00 6 0.05, Ast-Tbr2DN: 0.87 6 0.09, P 5 0.25). Thus, the primary effect of astrocytic TGFb signaling on these parameters was on the subacute upregulation of TGFb signaling after stroke.
To assess whether this overall decrease in subacute TGFb signaling meant that there was a global effect throughout the peri-infarct region (i.e., an effect on TGFb pathway activation in non-astrocyte cell types), we examined Akt pathway activation in neurons. We selected Akt phosphorylation because it is neuroprotective after ischemia and a neuronal target of TGFb signaling after stroke (Zhao et al., 2006; Zhu et al., 2004) . Indeed, Western blots for phosphorylated and total Akt indicated an overall decrease in Akt phosphorylation in the peri-infarct cortex of Ast-Tbr2DN mice 2 days after stroke compared with controls (Fig. 5E,F) . We next immunostained for pAkt 2 days after stroke and found that pAkt was primarily, although not exclusively, neuronal. It colocalized with the neuronal nuclear marker NeuN, and its immunostaining was decreased throughout the peri-infarct cortex in Ast-Tbr2DN mice (Fig. 5G) . Furthermore, when we quantified the percent of neurons that exhibited any nuclear pAkt immunostaining, there were significantly fewer pAkt 1 / NeuN 1 nuclei in Ast-Tbr2DN mice than in WT mice (Fig.   5H ). Thus, the relative deficiency in TGFb signaling after D) . E, F. Representative Western blot images (E) and quantification (F) of the TGFb downstream signaling mediator Akt phosphorylation in the peri-infarct cortex of wildtype controls and Ast-Tbr2DN mice 2 days after dMCAO. G. Representative images of pAkt colocalization with the neuronal nuclear marker NeuN and nuclear marker DAPI in wildtype controls and Ast-Tbr2DN mice 2 days after dMCAO. Scale bar, 20 lm. Arrows, wildtype neuronal nuclei showing pAkt immunostaining. Asterisks, Ast-Tbr2DN neuronal nuclei showing no pAkt immunostaining. H. Quantification of pAkt co-localization with neuronal nuclear marker NeuN in wildtype controls and AstTbr2DN mice 2 days after dMCAO. N 5 5-6 mice per group. Bars, mean 6 SEM. *P < 0.05, ***P < 0.001, Student's t test.
stroke in Ast-Tbr2DN mice causes decreased TGFb signaling in neurons as well as in astrocytes.
Inhibiting Astrocytic TGFb Signaling Worsens Motor Outcomes during the First Week after Stroke
The dMCAO stroke model does not produce motor deficits, so to investigate whether increased inflammation and neuronal damage in Ast-Tbr2DN mice is physiologically important for motor recovery, we targeted the motor cortex using the photothrombotic stroke model. As with dMCAO, there was no difference in infarct sizes early after stroke (Fig. 6A) . However, by 4 weeks we observed 1.5-fold larger strokes in Ast-Tbr2DN mice than in wildtype controls (Fig. 6B) .
To test motor outcomes, we subjected Ast-Tbr2DN mice and wildtype controls to the beam balance test as well as to a battery of motor tests, which are collectively known as the modified Garcia test, weekly for 4 weeks following photothrombotic stroke. Neither wildtype nor Ast-Tbr2DN mice showed any behavioral impairment at baseline.
In the beam balance test, Ast-Tbr2DN mice performed significantly worse during the first week after stroke (Fig. 6C) , though both genotypes achieved full recovery by 4 weeks. By comparison, neither genotype demonstrated full motor recovery in the modified Garcia test by 4 weeks after stroke. In this test Ast-Tbr2DN mice exhibited a larger motor deficit within the first week after stroke that persisted throughout the testing (Fig. 6D-H) . This deficit in AstTbr2DN mice appeared as a trend in subtests of limb symmetry, forelimb strength and lateral turning (Fig. 6D-F) and was highly significant in forelimb walking and climbing (Fig. 6G,H) . Overall, the combined motor test score indicated significantly worse motor outcomes in Ast-Tbr2DN mice (Fig. 6I) . Together, these results show that astrocytic TGFb signaling limits both infarct expansion and the severity of motor deficits.
Discussion
We demonstrate here that astrocytic TGFb signaling functions to limit immune cell infiltration and activation after stroke. Interestingly, the immunoregulatory effects of astrocytic TGFb signaling are a distinct mechanism, independent FIGURE 6: Ast-Tbr2DN mice develop larger infarcts and worse motor outcomes up to 4 weeks after photothrombotic stroke. A, B. Quantification of fold increase in infarct size in Ast-Tbr2DN mice compared with wildtype controls 1 day (A) and 28 days (B) after photothrombotic stroke. Bars, mean 6 SEM. *P < 0.05, Student's t test. C. Quantification of motor outcomes during the first 4 weeks after photothrombotic stroke using the Beam Balance Test. D-H. Quantification of motor outcomes during the first 4 weeks after photothrombotic stroke using tests for Limb Symmetry (D), Forelimb Strength (E), Lateral Turning (F), Forelimb Walking (G) and Climbing (H). I. Combined motor test score. N 5 10-12 mice per group. Bars, mean 6 SEM. *P < 0.05, **P < 0.01, ***P < 0.001, Mann-Whitney test and repeated measures ANOVA testing for differences between genotypes.
of the physical barrier formed by astrocytes: we observed no differences in the expression of GFAP and ECM components between mice with normal and reduced astrocytic TGFb signaling. Instead, our results are consistent with a model in which TGFb signaling in astrocytes upregulates beneficial TGFb signaling in the peri-infarct cortex during the subacute time window after stroke by upregulating the expression of TGF-b1 and its activator thrombospondin-1 (Fig. 7 ). This positive feedback loop then limits neuroinflammation and neuronal injury in the peri-infarct cortex via the immunosuppressive and neuroprotective functions of TGFb.
We found that astrocytic TGFb signaling limits the magnitude and spread of the immune response to stroke, but found no evidence that it affected immune cell polarization. Ast-Tbr2DN mice with reduced astrocytic TGFb signaling exhibited a twofold increase in the number of activated microglia and macrophages 2 days after stroke. We next quantified two markers of proinflammatory macrophages and microglia, MHC II and iNOS, and observed a corresponding twofold upregulation, consistent with twice as many cells rather than a change in immune cell phenotype. In addition, since Ast-Tbr2DN and wildtype stroke volumes were not significantly different at this time point, this excessive neuroinflammation was not caused by a difference in stroke size.
Excessive neuroinflammation in Ast-Tbr2DN mice was however associated with increased neuronal dysfunction and injury, represented by impaired motor recovery and late infarct expansion in the photothrombotic stroke model. The photothrombotic stroke model was used not only to measure motor outcomes but also to increase accuracy in measuring late infarct size because it produces a much larger stroke than the dMCAO model. In contrast, dMCAO in C57BL/6J mice does not produce a motor deficit, and the infarct cannot be easily measured by 4 weeks after stroke due to cortical atrophy. However, neither dMCAO nor photothrombotic stroke sizes were different between genotypes 1 day after infarction, before the peak immune response.
Neuronal dysfunction in Ast-Tbr2DN mice may have occurred secondary to the twofold increase in iNOS, which is known to be neurotoxic by stimulating free radical production (Brown, 2010) . In addition, both TGFb and TGFb pathway activation were also significantly lower in AstTbr2DN peri-infarct cortex 2 days after stroke. TGFb is well known to be directly anti-apoptotic and neuroprotective following stroke (Pang et al., 2001; Ruocco et al., 1999) , in part by activating the PI3K/Akt pathway that leads to Akt phosphorylation in neurons (Zhu et al., 2002 (Zhu et al., , 2004 . Indeed, we did observe a lower probability of nuclear pAkt immunostaining in Ast-Tbr2DN mouse neurons after stroke and an overall reduction in pAkt in peri-infarct cortex. Thus, when TGFb signaling is normally upregulated in wildtype mice in the subacute period after stroke it may provide neuroprotection against secondary injury in the peri-infarct cortex. However, it is important to note that TGFb signaling involves multiple pathways in addition to the classic canonical pathways mediated by Smads. The Akt pathway is only one of the noncanonical signaling pathways activated by TGFb. Other noncanonical pathways that it activates, such as MAPK and Erk mediated signaling (Zhang, 2009) , could also potentially affect TGFb-induced neuroprotection after stroke.
This study is, to our knowledge, the first time that an astrocytic signaling pathway has been shown to limit neuroinflammation without affecting the physical barrier formed by astrocytes. Either ablating proliferating GFAP 1 astrocytes or deleting the inflammatory mediator STAT3 in astrocytes reduces the physical barrier and increases immune cell infiltration after traumatic brain and spinal cord injuries (Bush et al., 1999; Wanner et al., 2013) . Similarly, expressing a dominant negative inhibitor of proinflammatory NF-jB signaling both increases astrocytic scarring and reduces the expression of proinflammatory cytokines after spinal cord injury and ischemia (Brambilla et al., 2005; Dvoriantchikova et al., 2009) . In contrast, here we found that when astrocytic TGFb signaling is inhibited, there is more immune cell infiltration without changes in the expression of GFAP or two other components of the physical barrier, tenascin-C, and fibronectin. Although inhibiting astrocytic TGFb signaling did not change the physical barrier formed by astrocytes, we did observe that it significantly altered cytokine expression in the peri-infarct cortex. Astrocytes with reduced TGFb signaling were unable to stimulate the expression of the injuryresponsive TGFb isoform TGF-b1 and its activator thrombospondin-1 in the subacute time window after stroke. Interestingly, thrombospondin-1 has not previously been implicated in TGFb activation after stroke. While our findings cannot exclude the existence of other TGFb activating molecules that are affected by astrocytic TGFb-signaling after stroke, thrombospondin-1 is known to be a major activator of TGFb in vivo (Crawford et al., 1998) , and TGFb is known to induce thrombospondin-1 transcription in astrocytes (Ikeda et al., 2010) .
Thus, our results indicate that instead of altering the physical barrier formed by astrocytes, TGFb signaling affects what the astrocytes secrete. We therefore speculate that in addition to their ability to generate a physical barrier, astrocytes form a "secretory" barrier to injury, composed at least in part by molecules such as TGFb that astrocytes secrete to limit neuroinflammation.
Our results further reveal that normal astrocytic TGFb signaling regulates this secretory barrier in a time and location-specific manner: inhibiting astrocytic TGFb signaling primarily affected the levels of active TGFb during the subacute time period and in the peri-infarct cortex. This subacute time window was also the critical time period in which TGFb signaling in GFAP 1 astrocytes was required to limit inflammation. By comparison, inhibiting astrocytic TGFb signaling had no effect on inflammatory cells or cytokines, astrocyte activation, or motor performance at baseline. Similarly, we did not observe any differences between genotypes on or after 7 days after stroke either in neuroinflammation or in worsening of the behavioral deficit. Thrombospondin-1 expression also returned to wildtype levels by 7 days, potentially because sufficient thrombospondin-1 was produced by activated microglia and macrophages (Lanz et al., 2010; Ortiz-Masia et al., 2012) . This temporal specificity suggests a clinically relevant time window to target astrocytic TGFb signaling for maximal benefit. In the context of previous studies on global differences in TGFb levels after injury, it was surprising that decreased astrocytic TGFb signaling did not reduce GFAP expression and alter the astrocytic scar after stroke. TGF-b1 directly stimulates astrocytic expression of GFAP (Reilly et al., 1998; Romao et al., 2008) as well as the ECM components fibronectin and tenascin-C (Schachtrup et al., 2010; Smith and Hale, 1997) . In addition, mice that overexpress mutant, constitutively active TGF-b1 in the hippocampus have increased GFAP expression (Wyss-Coray et al., 1997) , while global depletion of TGFb reduces GFAP expression after traumatic brain injury (Logan et al., 1994; Yoshioka et al., 2011) . By contrast, we show that inhibiting endogenous astrocytic TGFb signaling and global TGFb upregulation did not affect the expression of these physical barrier components. This incongruity could be caused by differences in TGFb activation between injury models, or because global TGFb signaling in our model was partially rather than completely inhibited. Alternatively, increased immune infiltration in AstTbr2DN mice early after stroke could increase GFAP expression via another pathway, for example, NF-jB signaling (Gao et al., 2013; Krohn et al., 1999) , which would compensate for reduced GFAP expression caused by reduced astrocytic TGFb signaling.
In conclusion, we demonstrate that inhibiting endogenous astrocytic TGFb signaling during the subacute period after stroke prevents the upregulation of functional TGFb and its signaling in the peri-infarct cortex and strongly exacerbates infiltration and activation of innate immune cells. Because TGFb is upregulated universally in acute and chronic brain injury, it may represent a universal pathway that mediates the endogenous immunoregulatory functions of astrocytes. The anti-inflammatory and prorecovery functions of astrocytic TGFb signaling may therefore extend to other acute insults, such as traumatic brain injury or CNS infection, which are also characterized by increased TGF-b1 (Buckwalter and Wyss-Coray, 2004) .
